Stock Market

A technician prepares a flow cell slide for loading onto a genetic sequencing machine at a Regeneron Pharmaceuticals laboratory at the biotechnology company’s headquarters in Tarrytown, New York Mike Segar | Reuters Check out the companies making headlines in midday trading.  Regeneron — Shares of the biotech company rose 5.9% after President Donald Trump used
0 Comments
by confoundedinterest17 In 1995, The Clinton Administration unleashed a BAD housing policy called The National Homeownership Policy that called on “partners” to streamline mortgage lending standards to increase homeownership rates (allowing ALT-A lending). It worked, but it also drove home prices through the roof. And it exploded nearly destroying the banking system. Not learning from past housing follies, Presidential
0 Comments
by Lance Roberts Every three years, the Federal Reserve releases a study on consumer finances that is a stockpile of data on everything from household net worth to incomes. The 2019 Fed survey confirms statements I have made previously regarding how the Fed’s monetary interventions made the top 10% more prosperous than ever. They just left the vast majority
0 Comments
Shares of Smart Global Holdings plunged 12.1% On Friday after the company reported lower-than-expected 4Q top-line results. On Oct. 1, the manufacturer and supplier of electronic subsystems reported revenues of $297 million, which fell short of analysts’ expectations of $299.4 million. Smart Global’s (SGH) 4Q revenues improved 6.7% from the year-ago quarter. Meanwhile, adjusted EPS
0 Comments
by Flamehuntz www.law.cornell.edu/uscode/text/50/842 50 U.S. Code § 842.Proscription of Communist Party, its successors, and subsidiary organizations The Communist Party of the United States, or any successors of such party regardless of the assumed name, whose object or purpose is to overthrow the Government of the United States, or the government of any State, Territory, District, or possession
0 Comments
11 months ago, the U.S. Food and Drug Administration (FDA) shut down Solid Biosciences’ (SLDB) “IGNITE DMD” Phase I/II clinical trial after one of the young patients involved in the trial suffered a “serious adverse event.” Despite the patient in question recovering, no new patients suffering such serious adverse events, and the company providing the
0 Comments
BY JOHN RUBINO  Money managers who don’t recommend gold to their clients are becoming the exception rather than the rule. This week saw a couple more big-name banks join the pro-gold parade: (RT) – The recent weakness of gold represents a “great entry point for investors” ahead of risk events such as the US election, said UBS Global
0 Comments
It is hard to argue with Amazon’s (AMZN) performance in 2020. Even amidst a global pandemic and a struggling economy, all the cards have fallen into place for the e-commerce behemoth. Amazon has seen revenue soar during the viral outbreak and so has its stock. Shares are up by 70% on a year-to-date basis. However,
0 Comments
by confoundedinterest17 Look at these indicators: The Philadelphia Stock Exchange Housing Sector Index, Semiconductor Index and Gold relative to The Federal Reserve’s Balance Sheet of Asset Purchases. How much of the gain in these indices is the result of Fed monetary stimulus? Stated differently, what happens when The Fed can’t print anymore money??
0 Comments
On Wednesday, the IMF released the latest Currency Composition of Official Foreign Exchange Reserves (COFER) report for Q2 2020. It showed that while the Dollar share of global reserves had increased in Q1 2020, likely on a combination of valuation effects and safe-haven demand, trend reversed abruptly in Q2 as shown in the Goldman chart below. The
0 Comments
by mistasway The divisive rhetoric from the MSM will be cranked up the next few weeks. On the surface, it will appear as if there’s this great battle between two “teams”, but in reality it’s basically this scripted WWE style drama, solely for the purpose of stirring the pot and creating animosity and tension among
0 Comments
Ligand Pharmaceuticals announced that it has completed the acquisition of Pfenex Inc. for $437.5 million in cash. The biopharmaceutical company said that it would make a “contingent payment of $78 million in cash if a certain specified milestone is achieved.” The deal was announced in August this year. Ligand shares closed 3.02% higher on Thursday. Ligand
0 Comments